“The data found EXPAREL use associated with improved clinical outcomes and a favorable cost savings per patient compared to the standard of care,” said a release.
EXPAREL was associated with a shorter length of hospital stay, greater mobility after surgery and a savings of $366 per patient on direct hospital costs.
“While our results were specific to a single institution and surgery type, we believe our methodology could serve as a model for minimizing the biases which often confound drug utilization evaluation studies, and help other institutions accurately assess the utility of EXPAREL,” said Carmen S. Kirkness, PT, PhD, who co-led the study.
More articles on orthopedics:
Orthopedic surgeon to know: Dr. David Jacofksy of The CORE Institute
ACL surgery: 5 things to know about health-related quality of life
Coordinated Health acquires Orthopedics Associates of the Greater Lehigh Valley
